CHDI
HudsonAlpha and CHDI Foundation announce Huntington disease collaboration
Project will study gene regulatory network of genetic neurodegenerative disorder Huntsville, Ala. — HudsonAlpha Institute for Biotechnology ...Read More
Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington’s Disease Completed and Open-Label Extension Study to Open in 2H 2017
CARLSBAD, Calif., June 22, 2017 -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients ...Read More
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
VY-HTT01 Selection Based on Robust Knockdown of Huntingtin in Preclinical Studies Program On Track for IND Filing in 2018
Cambridge, Mass., June 1, 2017 – Voyager Therapeutics, I ...Read More12th Annual HD Therapeutics Conference
Coming soon… online hosting of the presentations from the Malta conference. ...Read More
Critical Path Institute and CHDI Foundation, Inc. establish a consortium to expedite approval of Huntington’s disease therapeutics
TUCSON, Arizona, October 31, 2016 — Critical Path Institute (C-Path) and CHDI Foundation, Inc., are collaborating to set up a broad-based consortium that will more clearly ...Read More
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS) today announced a researc ...Read More
11th Annual CHDI HD Therapeutics Conference 2016
Monday-Thursday, February 22-25, 2016 Click Here for the Conference Program, Speaker Abstracts, and Poster Abstracts. ...Read More
Isis Pharmaceuticals initiates clinical study of ISIS-HTTRx in patients with Huntington’s disease
First therapy designed to directly target the cause of disease Isis earns $22 million milestone payment from Roche Carlsbad, Calif., July 21, 2015 –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced ...Read More